Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias
about
Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.Matrix-assisted refolding and purification of placenta-derived recombinant human interleukin-6 produced in Escherichia coli.Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.Multiple Myeloma and Chronic Lymphocytic Leukemia: Commonalities and Differences in Biology and Therapy.Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.Interleukin-10 and Gp130 cytokines in human multiple myeloma.HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple MyelomaInterleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.The clinical usefulness of the measurement of cytokines.Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancerThe therapeutic potential of interleukin-6 hyperagonists and antagonists.Myelomagenesis: capturing early microenvironment changesInterleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsDilemmas in treating smoldering multiple myeloma.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesGP130 activation induces myeloma and collaborates with MYC.Survival and proliferation factors of normal and malignant plasma cells.Salmonella typhi stimulation of human intestinal epithelial cells induces secretion of epithelial cell-derived interleukin-6.Role of monocytes in atherogenesis.Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?Bone marrow microenvironment and the progression of multiple myeloma.Association between Serum Levels of Interleukin-6 and Stage of Laryngeal CancerDefective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.Polymorphisms in immune function genes and non-Hodgkin lymphoma survival.Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice.The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130Interleukin 6 is essential for in vivo development of B lineage neoplasms.Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease modelsRANKL/RANK/OPG: key therapeutic target in bone oncology.Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.Body mass index, physical activity, and risk of multiple myeloma.Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2.URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.
P2860
Q28204011-56CA74A3-268C-47B7-B6EC-614F1981876AQ30571858-2E0F35BD-8996-4CF4-A4E2-CF395BDA997FQ31147299-43E88C9D-6563-493C-AFED-AA81681CC2ECQ33394977-DC5334B1-0966-42CC-8009-52DEE908F63BQ33434182-FCE18BA2-344E-4C94-97F7-79557485CA44Q33503487-DAA28843-B695-4431-BF89-FBEEAEC0B873Q33577408-C45FA6F5-CF1D-427E-BBED-B9235DC7FBEDQ33647931-4EC664E8-C836-449E-B703-9F073EBE0AD2Q33794361-325FE843-947B-41E2-901B-3049E9413C16Q33868508-E87D10F2-CE38-4937-A8F3-BA1EC671E805Q33907983-C866C138-9090-4A28-AA4D-D190D2875659Q33992704-2237ED8D-3DD9-4651-99CD-94ECA47E23B8Q34123869-651782B0-45D5-479E-956A-9A27A878D56AQ34430168-40282238-01A2-4040-95B1-861F3AC72FD8Q34519296-B10208AE-76DC-46C3-ADFF-682BE7396C4BQ34571230-CA80A365-8AC7-4ADC-8D2D-5809E0BB8282Q34716500-0F14A72D-A047-4B94-BB7F-E748AE0803DCQ35132241-877E403D-643C-434A-B766-38DCCA3CC7B8Q35145350-C41E5920-A5CC-4E80-AA59-C3D28A4A6BC8Q35211028-1699FD8D-CDE7-48A1-BC9D-57B3A2A12114Q35534558-AE350250-FBEC-463E-9E14-CDA3D8528978Q35541858-4C14C8D2-9E56-4B58-8F33-FE4A1E8D5EAFQ35584599-6A8847B5-1FBB-4E4F-BFB7-E32ABB82553FQ35664731-46FE4F9B-430A-4814-A8E8-97524C489DBBQ35708994-844DB18D-0481-409D-8FA2-6224E1699C92Q35763419-A534F151-FA3A-4993-828B-A2397BAEEC4CQ35824530-83A4EEBC-47CD-4D5F-8206-7B3726315ACBQ35889753-F2959849-4DF3-4276-95A8-C0BC906BACBFQ35976882-C9CBD24A-9A93-41DB-93E4-F4A4122A7055Q36081225-426CA1C0-C703-45C7-A660-2715DAA303E9Q36362977-B672E8DA-E16F-4B97-97CF-DC348C6C9CC2Q36365082-2D766275-839A-4A00-8EDB-AB7528F4D7DDQ36628145-6D0BE476-AF19-4962-9B55-AD5F997F0FDEQ37140665-9AAB925D-24E9-4DE9-9E57-367D150E06A1Q37359948-FD16D8AE-BCD4-4222-B0B1-57F3956B1B12Q37387180-CF8DC688-3065-488B-A70D-94073BE86F9EQ37407676-68729B46-DBA9-45B1-BC82-5257157D7714Q37608027-8215A308-DEA0-4E5B-ADD2-A15C3DE7583BQ37680154-74A2B691-F3F6-42DE-B2FE-9A18948E4D96Q37880074-69EA9235-2DC2-4A19-903A-5E96EBCAFA1A
P2860
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias
description
1989 nî lūn-bûn
@nan
1989 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
name
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@ast
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@en
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@nl
type
label
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@ast
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@en
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@nl
prefLabel
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@ast
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@en
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@nl
P2093
P2860
P356
P1476
Serum levels of interleukin 6, ...... rity in plasma cell dyscrasias
@en
P2093
P2860
P304
P356
10.1172/JCI114392
P407
P577
1989-12-01T00:00:00Z